Monitor for upcoming earnings or clinical trial updates; coordinated selling by multiple C-suite executives may signal lack of near-term confidence despite recent price strength. Consider hedging if positioned long.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $33.19entry
- T+1 · 8mo ago +2.32%α +1.30% · $33.96
- T+5 · 8mo ago +0.96%α +3.08% · $33.51
- T+20 · 7mo ago +5.60%α +2.02% · $35.05
- T+60 · 5mo ago −12.62%α −24.24% · $29.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven open-market share sales by four insiders at Stoke Therapeutics over the past week, including the CFO, Chief Medical Officer, General Counsel, and Chief Patient Officer, totaled approximately $772,200 in proceeds. The transactions include both routine sales and derivative exercises, with the majority of economic activity representing open-market selling.
Key Financial Metrics
Key Facts
- CFO (Leggett Thomas) sold $67,980 worth of shares in open-market transaction
- Chief Medical Officer (Ticho Barry) sold $234,647 in shares and exercised derivatives for 2,730 shares (non-cash value of $2,989)
- General Counsel (Allan Jonathan) sold $424,439 in shares across two days
- Total open-market sales by insiders: $772,207
- All sales occurred between $29.99 and $33.64 per share
- No open-market purchases reported in the cluster
Financial Impact
$772,207 in net insider selling over 7 days
Risk Factors
- Perception of insider pessimism due to absence of offsetting buys
- Potential for further selling if near-term catalysts disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-STOK-1774383582951 |
Track record
18 reports on STOK
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers